Cardinal Health Expands Actinium-225 Production Line, Quadruples Weekly Output
Cardinal Health has installed a high-capacity Actinium-225 production line at its Indianapolis Center for Theranostics Advancement, boosting cGMP-compliant output. Since late 2024, weekly Ac-225 production has quadrupled, and capacity will further increase throughout 2026 to meet rising demand for targeted alpha therapies.
1. Production Expansion
Cardinal Health has added a high-capacity Actinium-225 production line to its Center for Theranostics Advancement in Indianapolis, updating its Drug Master File to increase supply of cGMP-compliant Ac-225 for investigational and future commercial therapies.
2. Output Growth and Future Capacity
Weekly Ac-225 output has quadrupled since routine global production began in late 2024, and the company plans further capacity increases throughout 2026 to address a rapidly growing market for targeted alpha therapies.
3. Market Demand and Clinical Pipeline
Ac-225 is used in novel targeted alpha therapies for prostate, neuroendocrine, breast, colon, melanoma and lymphoma, with Cardinal Health’s supply supporting more than 15 clinical trials worldwide, highlighting critical demand in oncology research.
4. Strategic Significance
Expanded Ac-225 capacity strengthens Cardinal Health's position in nuclear medicine supply chains, underpins future commercial volumes and supports global regulatory applications for cGMP-compliant material across multiple regions.